A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Pain [EXTENSION OF 700054125]

Trial Profile

A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Pain [EXTENSION OF 700054125]

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Back pain; Musculoskeletal pain; Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top